Characterization of Neutralizing Anti-Drug Antibody Response in Patients With Loss of Response to Anti-TNF Therapy

被引：0
|
作者：
Hauenstein, Scott
Salbato, Jared
Lockton, Steven
Singh, Sharat
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [31] Interest of Assessing Anti-Drug Antibodies for the Choice Between a Second Anti-TNF and a Non-TNF-Targeted Biologic in Patients with Inadequate Response to a First Anti-TNF : Results from the Randomized Controlled Trial "Rotation or Change"
    Candon, Sophie
    Chatenoud, Lucienne
    Brocq, Olivier
    Perdriger, Aleth
    Lassoued, Slim
    Berthelot, Jean-Marie
    Wendling, Daniel
    Euller-Ziegler, Liana
    Soubrier, Martin
    Richez, Christophe
    Fautrel, Bruno
    Constantin, Arnaud
    Mariette, Xavier
    Morel, Jacques
    Gilson, Melanie
    Cormier, Gregoire
    Salmon, Jean Hugues
    Bouillon, Stephanie Rist
    Liote, Frederic
    Marotte, Hubert
    Bonnet, Christine
    Marcelli, Christian
    Sellam, Jeremie
    Meyer, Olivier
    Solau-Gervais, Elisabeth
    Guis, Sandrine
    Ziza, Jean Marc
    Zarnitsky, Charles
    Chary-Valckenaere, Isabelle
    Vittecoq, O.
    Saraux, Alain
    Pers, Yves-Marie
    Gayraud, Martine
    Bolla, Gilles
    Claudepierre, Pascal
    Ardizzone, Marc
    Labous, Emmanuelle Dernis
    Breban, Maxime A.
    Fain, Olivier
    Balblanc, Jean Charles
    Perrodeau, Elodie
    Sibilia, Jean
    Ravaud, Philippe
    Gottenberg, Jacques
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [32] ANTI-DRUG ANTIBODIES, DRUG LEVELS AND CLINICAL EFFICACY OF THE ANTI-TNF BIOLOGICS IN RHEUMATIC DISEASES
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 226 - 226
  • [33] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    C. C. Mok
    D. van der Kleij
    G. J. Wolbink
    Clinical Rheumatology, 2013, 32 : 1429 - 1435
  • [34] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G. J.
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1429 - 1435
  • [35] THE PRESENCE OF ANTI-NUCLEAR ANTIBODIES BEFORE ANTI-TNF THERAPY IS A RISK FACTOR FOR THE APPEARANCE OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kumagai, Shunichi
    Mori, Ayano
    Saito, Toshiharu
    Takahashi, Miho
    Yoneda, Katsuhiko
    Noda, Yasuhiro
    Takahashi, Soushi
    Nishida, Miwa
    Hatachi, Saori
    Tsuji, Goh
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1149 - 1150
  • [36] VEDOLIZUMAB IS AN EFFECTIVE THERAPY IN POSTOPERATIVE ILEAL CROHNS FOLLOWING LOSS OF RESPONSE TO ANTI-TNF
    Saffouri, E.
    Kemp, L.
    Muir, A.
    Richardson, G.
    Morrison, P.
    Watts, D.
    GUT, 2017, 66 : A119 - A119
  • [37] Predicting Response to Anti-TNF Treatment in RA Patients
    Middleton, D.
    Harvie, J.
    Steven, M.
    SCOTTISH MEDICAL JOURNAL, 2010, 55 (01) : 43 - 43
  • [38] Predictors of response to anti-TNF agents in patients with RA
    Nature Clinical Practice Rheumatology, 2007, 3 (3): : 127 - 127
  • [39] Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies
    Anjie, Suzanne I.
    Hanzel, Jurij
    Gecse, Krisztina B.
    D'Haens, Geert R.
    Brandse, Johannan F.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2024, 59 (02) : 169 - 175
  • [40] Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease
    Guerra, Ivan
    Chaparro, Maria
    Bermejo, Fernando
    Gisbert, Javier P.
    CURRENT DRUG METABOLISM, 2014, 15 (09) : 875 - 881
12345